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ABSTRACT  
Background: Nonalcoholic fatty liver disease is a 
common finding in obese subjects. Increasing 
evidence has been provided suggesting that it 
represents the hepatic component of the metabolic 
syndrome.  
Objective: Aim of this longitudinal study was to 
evaluate the relationships between several 
anthropometric measures, including the hepatic 
left liver lobe volume (HLLV), and various 
indicators of the metabolic syndrome in a cohort 
of severely obese women before and after 
Laparoscopic Adjustable Gastric Banding 
(LAGB).  
Study design and results: Seventy-five obese 
women (mean age 45 ± 10 years and Body Mass 
Index - BMI 42.5 ± 4.8 Kg/m
2
) underwent LAGB 
and completed an average (± SD) post-surgical 
follow-up of 24 ± 6 months. Determination of 
HLLV, subcutaneous and intra-abdominal fat was 
based on ultrasound. Principal Component 
statistical Analysis (PCA) applied to pre-operative 
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measurements, highlighted HLLV as a parameter 
that clustered with serum insulin, intra-abdominal 
fat, serum glucose and uric acid, along with 
triglycerides, alkaline phosphatase and HDL 
cholesterol. After LAGB, the average reduction of 
BMI was 23%, 12% for subcutaneous fat, 42% for 
HLLV and 40% for visceral fat. Among body 
weight, BMI, subcutaneous fat, intra-abdominal 
fat and HLLV, reduction of the latter was an 
independent predictor of reduction of serum 
transaminases and γ-glutamyltransferase, glucose, 
insulin, and triglycerides.   
Conclusions: in severely obese women i) HLLV 
is a sensitive indicator of ectopic fat deposition, 
clustering with parameters defining the metabolic 
syndrome; ii) weight loss achieved by LAGB is 
associated with a reduction of liver volume as 
estimated by HLLV; iii) among various 
anthropometric parameters measured, reduction of 
HLLV that follows LAGB represents the best 
single predictor of improvement of various 
cardiometabolic risk factors. 
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INTRODUCTION 
With the growing epidemic of obesity and the 
associated increasing prevalence of the metabolic 
syndrome
1-4
, much interest has arisen on the 
hepatic manifestations that develop as a 
consequence of visceral fat accumulation
5-7
  . 
Non-alcoholic fatty liver disease (NAFLD) is now 
recognized as the most common cause of 
abnormal liver tests. NAFLD is defined by a lipid 
accumulation >5% in hepatic tissue in the absence 
of chronic alcohol consumption
8
.  NAFLD is 
characterized by a wide spectrum of liver damage 
ranging from simple steatosis to advanced fibrosis 
and to cryptogenic cirrhosis through steato-
hepatitis (NASH), and, ultimately, to 
hepatocellular carcinoma
9,10
. The prevalence and 
severity of NAFLD increases with increments of 
body mass index (BMI)
11-13
 and steatosis is 
observed in up to 86% of severely obese 
patients
11, 14
 
NAFLD is usually asymptomatic and 
hepatomegaly can be the only objective sign. No 
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combination of clinical or biochemical 
abnormalities can accurately differentiate the 
spectrum of NAFLD, and only liver biopsy can 
establish with certainty the diagnosis. However, 
whole hepatic enlargement is proportional to the 
severity of the metabolic syndrome, and various 
imaging methodologies can be used for the 
estimation of liver volume
15, 16
. We have recently 
introduced an ultrasound technique that measures 
the Hepatic Left Lobe Volume (HLLV), 
calculated by the ellipsoid formula, and we have 
shown that HLLV is tightly correlated to and thus 
an excellent indicator of visceral adiposity
17
.   
Treatment of obesity is based upon low-calories 
diets, behavioural modifications and physical 
activity, the pharmacological treatment being 
considered as further approach. Unfortunately, 
particularly in patients with severe obesity, the 
results of these approaches are often 
disappointing, with many patients either losing an 
inadequate amount of weight or experiencing total 
weight regain within a short period of time. 
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Several surgical procedures have therefore been 
developed which have proven to be effective in 
achieving 1) a long term weight loss 2) reducing 
the mortality rate and 3) improving the co-
morbidities associated with the disease
18-23
.  
The aim of this longitudinal study was to evaluate 
the relationships between several anthropometric 
measurements, including the HLLV, and various 
indicators of the metabolic syndrome in a cohort 
of severely obese women before and after 
bariatric surgery. Of particular interest to us were 
the effects of weight loss on liver volume, in 
parallel with amelioration of various co-
morbidities, in obese women treated by 
Laparoscopic Adjustable Gastric Banding 
(LAGB). LAGB was chosen because it produces a 
sustained weight loss without major alterations of 
the anatomy and physiology of the gastrointestinal 
tract
24, 25
.  
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SUBJECTS AND METHODS 
In this study 75 consecutive obese women were 
included, who underwent LAGB and completed 
an average (± SD) post-surgical follow-up of 24 ± 
6 months. Patients of our study belonged to a 
cohort of 145 women who underwent gastric 
banding during the same time period. Among 
them, 33 women could not be included because of 
the selection criteria described below. Thirty 
women could not be enrolled because of missing 
information due to unintentional events that 
precluded the collection of the entire dataset, 
while 7 subjects were lost at follow up.  
The mean age of the 75 patients was 45 ± 10 years 
(range 22−67 years), the mean body weight was 
110.7 ± 14.8 Kg (range 78.5−148 Kg), and the 
mean BMI was 42.5 ± 4.8 Kg/m
2
 (range 
33.9−55.7 Kg/m2). 
None of the patients was taking hypoglycemic, 
hypolipemic or hypouricemic agents (18 were 
taking anti-hypertensive drugs). Additional 
exclusion criteria were: self-reported alcohol 
 8 
consumption > 20 g daily, use of illicit drugs or 
hepatotoxic medications, viral hepatitis as 
assessed by conventional serum markers, 
pregnancy or breast feeding within the 12-months 
period before enrolment. Clinical, hematological, 
and instrumental examinations of each patient 
were performed following the Italian guidelines 
for obesity, and each patient was treated 
according to appropriate protocols for her 
condition. Anthropometric measures were 
determined after an overnight fasting. Body 
weight was measured to the nearest kilogram, 
while height and abdominal circumference were 
determined to the nearest centimeter.  
Venous blood samples were obtained after an 
overnight fasting for measurement of serum 
glucose, triglycerides, total cholesterol, HDL-
cholesterol, uric acid, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), -
glutamyltransferase (GGT), alkaline phosphatase 
(ALP), erythrocytes sedimentation rate (ESR) and 
insulin. The homeostasis model of insulin 
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resistance (HOMA) was calculated based on 
fasting serum glucose and insulin 
concentrations
26
. Ultrasound examination for 
determination of HLLV, subcutaneous and intra-
abdominal fat was performed as previously 
described
17
. Briefly, the ellipsoid formula (width x 
height x length x 0.52) was applied to calculate 
the HLLV. The height of the lobe was obtained by 
an epigastric-longitudinal scan, considering the 
distance between the diaphragm and the lower 
margin of the left lobe. The length of the lobe was 
calculated on the axial scan by drawing a line 
between the round ligament and the lateral margin 
of the hepatic lobe. Thickness was obtained on 
both the axial and the longitudinal scans, 
measuring the distance between the anterior and 
the posterior borders of the liver. Thickness of the 
abdominal subcutaneous fat was taken 1 cm over 
the transversal umbilical vein, by measuring the 
distance between the skin and the external face of 
the muscular fascia, while intra-abdominal fat 
thickness was defined as the distance between the 
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internal face of the same muscle and the anterior 
wall of the aorta. 
All patients underwent LAGB (Swedish 
Adjustable Gastric Band by Ethicon Endosurgery, 
Johnson and Johnson, New Brunswick, NJ, USA) 
performed by the same surgeon. At the time of 
post-surgical evaluation, the same clinical, 
hematological, and instrumental examinations 
were repeated as already described. 
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STATISTICAL ANALYSIS 
The Principal Component Analysis (PCA)
27
 based 
on standardized parameters (i.e. anthropometric 
and hematological measurements) was applied in 
order to identify groups of correlated variables. 
Namely, PCA is a dimensional reduction 
technique which seeks the best linear 
combinations of variables (the Principal 
Components − PCs) that account for most of the 
variance of the total data. PCs are found to be 
uncorrelated from each other and ordered in 
decreasing way of explained variance so that the 
first PC is the best linear combination of variables 
that accounts for most of the variability, the 
second PC for most of the residual variance 
(uncorrelated with the first PC), and so on until all 
variability is explained by all calculated PCs. 
The number of significant PCs was determined 
using the scree test criterion
27
 by plotting the 
percentage of explained variance by each PC 
versus their rank (i.e. the scree plot) and further 
confirmed by the Parallel Analysis statistical 
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approach
28
. The Pearson correlation coefficient 
(i.e. PCA loading) and the squared cosine index 
were employed to quantify the contribution of 
each variable on extracted PCs in order to 
highlight clusters of correlated variables.  
Student’s t-test for paired data was used to 
evaluate differences before and after LAGB 
intervention for all variables. Logarithmic 
transformations of skewed variables were 
employed, as needed. 
For each parameter (dependent variable), a 
multiple linear regression analysis using a forward 
stepwise selection algorithm was employed to 
determine the significant predictors among 
independent variables (p-value in < 0.05). The R
2
 
statistic was employed to quantify the 
contribution of explained variance by the 
significant predictor selected at each step. 
Data analysis was performed using Matlab (the 
Mathworks®) and statistical significance was 
assumed for p-values < 0.05. Data are presented 
as mean ± standard deviation (SD). Statistical 
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analysis was conducted by PP and AL from the 
Department of Energy and Systems Engineering, 
University of Pisa. 
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RESULTS 
Anthropometric and hematological parameters 
before and after LAGB 
Table shows the values of anthropometric and 
metabolic measurements obtained before and two 
years after LAGB in our cohort of 75 severely 
obese female patients. 
As expected, after bariatric surgery a marked 
reduction of body weight was observed. Weight 
loss was associated with a significant reduction of 
subcutaneous fat and with an even more 
pronounced reduction of intra-abdominal fat and 
HLLV.  
Significant reductions of serum glucose, uric acid, 
triglycerides, ESR, ALP, AST, ALT and GGT 
were also noticed, together with a marked 
reduction of serum leptin and fasting insulin. 
Insulin-resistance (as assessed by the HOMA 
index) decreased, while HDL cholesterol 
significantly increased. 
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PCA of data obtained before LAGB  
As a result of PCA scree plot and Parallel 
Analysis, all parameters measured before surgery 
could be clustered in two components (PCs) 
explaining together 38% of the total variance.  
HLLV (r = 0.73), HOMA index (r = 0.71), insulin 
(r = 0.66), intra-abdominal fat (r = 0.62), GGT (r 
= 0.56), serum glucose (r = 0.55) and uric acid (r 
= 0.52) were mainly represented on the PC1 
(squared cosines on PC1 > 60%, p<0.01) that 
accounted for 26% of the total variance; 
furthermore, smaller but significant contributions 
to this cluster of variables were given by 
triglycerides (r = 0.40), ALP (r = 0.38) and, 
inversely, by HDL cholesterol (r = –0.34) .  
Body weight (r = 0.62) along with small 
contributions by total cholesterol (r = –0.33) and 
leptin (r = 0.31) were mostly associated with the 
PC2 (squared cosines on PC2 > 60%, p<0.05) that 
explained an additional 12% of the total variance.  
BMI (rPC1 = 0.60, rPC2= 0.60; squared cosine = 
50% on both PC1 and PC2), AST (rPC1 = 0.57, 
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rPC2 = – 0.66; squared cosines = 43 % on PC1 and 
57% on PC2), ALT (rPC1 = 0.60, rPC2= –0.64; 
squared cosines = 47 % on PC1 and 53% on PC2) 
and ESR (rPC1 = 0.34, rPC2= 0.30; squared cosines 
= 57 % on PC1 and 43% on PC2) were associated 
with both PCs. 
PCA loadings are shown in Figure 1 where the 
absolute values of the correlation coefficients 
between each variable and the PC1 (x-axis) are 
plotted against those related to the PC2 (y-axis). 
HLLV, HOMA index, insulin, IAF, serum 
glucose, uric acid, ALP, TG and HDL cholesterol 
best clustered together, whereas body weight, 
BMI, AST, ALT and GGT were grouped in a 
different cluster. ESR, total cholesterol, leptin and 
subcutaneous fat clustered in a third distinct 
group. 
In summary, these results suggest that HLLV is an 
anthropometric parameter that clusters with those 
strictly related to the metabolic syndrome and is a 
sensitive indicator of visceral adiposity. 
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Multivariate analysis of changes after LAGB  
The relationship between improvements of 
various serum parameters (dependent variables) 
and reduction of various anthropometric measures 
(independent variables) was analyzed by multiple 
regression analysis using a forward stepwise 
algorithm. Reductions of liver enzymes AST 
(R
2
=23%, p<0.01) and ALT (R
2
=23%, p<0.01) 
were related only to reduction of HLLV while 
reduction of GGT was correlated to both 
reduction of HLLV (R
2
=14%, p<0.01) and to 
reduction of BMI (additional R
2
=6%, p<0.05). 
The reductions of serum glucose (R
2
=16%, 
p<0.01), HOMA index (R
2
=16%, p<0.01) and 
triglycerides (R
2
=10%, p<0.01) were 
independently associated only with reduction of 
HLLV (Figure 2) while reduction of fasting 
insulin was related both to reduction of HLLV 
(R
2
=13%, p<0.01) and to reduction of body 
weight (additional R
2 
= 5%, p<0.05). 
The post-surgical reductions of ALP (R
2
=18%, 
p<0.01), ESR (R
2
=9%, p<0.01), leptin (R
2
=6%, 
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p<0.05) and the increase of HDL (R
2
=13%, 
p<0.01) were independently associated only with 
reduction of body weight. Finally, reduction of 
uric acid was associated both with reduction of 
intra-abdominal fat (R
2
=18%, p<0.01) and with 
reduction of BMI (additional R
2
=5%, p<0.05). 
Various results from multivariate analyses are 
summarized in Figure 3. 
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DISCUSSION 
BMI is the measure commonly used to define and 
classify obesity. However, BMI does not fully 
predict the morbidities associated with abnormal 
fat accumulation. Abdominal obesity is more 
closely associated with cardiovascular risk than 
gluteo-femoral obesity is, and a large body of 
studies indicates that waist circumference and the 
waist-to-hip ratio are better predictors of 
cardiovascular risk, morbidity and mortality than 
BMI
29-31
, particularly in severe obesity
32
. A failure 
in the capacity of subcutaneous fat to accumulate 
additional energy might be associated with 
storage of the lipid surplus in ectopic fat depots. 
Lipid deposition in tissues such as liver, skeletal 
muscle and visceral fat is thought to be involved 
in the pathogenesis of insulin resistance, 
atherogenic dyslipidemia and a chronic low grade 
systemic pro-thrombotic inflammatory state
7
. Yet, 
simple measurements of abdominal 
circumferences, while extremely powerful in 
epidemiological studies, may not be sufficient to 
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identify the single patient at high risk of 
cardiovascular disease and diabetes mellitus, in 
particular in severely obese subjects in whom the 
excess of subcutaneous fat may lead to an over 
estimation of intra-abdominal fat depots. The need 
of proper assessment of regional fat distribution 
by imaging techniques has been advocated, to 
establish the relationship between ectopic fat 
deposition and relevant metabolic markers, and to 
facilitate the identification of obese individuals 
who are at increased risk of cardiovascular disease 
and thus better candidates for interventions, 
including bariatric surgery
7
. With this aim, we 
have recently developed an easy, safe, repeatable 
and low-cost technique that allows a precise 
determination of Hepatic Left Lobe Volume 
(HLLV) during routine abdominal ultrasound 
examination
17
, and we have shown that HLLV is a 
sensitive indicator of visceral adiposity in obese 
subjects.  
In the present study we have expanded our 
previous observation by applying a statistical 
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analysis (PCA) able to identify clusters of 
correlated variables in obese patients scheduled 
for bariatric surgery. PCA confirmed a strong 
association between HLLV, visceral fat, various 
parameters of the metabolic syndrome and liver 
enzymes, while body weight, BMI and leptin co-
segregated within a different component. Two 
years after bariatric surgery, our patients achieved 
a significant weight loss and a concurrent 
reduction of intra-abdominal fat and HLLV was 
demonstrated. A parallel improvement of various 
cardio-metabolic risk factors was also observed. 
When the single components of the metabolic 
syndrome were analyzed (serum glucose, 
triglycerides, fasting insulin and HOMA), their 
reduction was independently associated only with 
the reduction of HLLV. Clamp studies would 
have been more informative to assess peripheral 
insulin resistance and their lack is a limitation of 
our study. Yet, we believe that the correlations 
observed in our large cohort of patients reinforce 
the role of hepatic volume as a powerful index of 
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visceral adiposity and associated insulin-
resistance. Reduction of serum transaminases and 
GGT in association with reduction of liver volume 
confirms the amelioration of liver disease 
observed in patients who have undergone 
LAGB
33
. Reduction of serum HDL was related 
only to reduction of body weight, indicating that 
regulation of this lipo-protein may be influenced 
by other factors beside ectopic fat accumulation. 
Similar explanations can be proposed for uric acid 
and ESR, while serum leptin was found reduced 
secondary to the drop of body weight, and thus of 
total body fat. The independent association 
between reduction of ALP and BMI is intriguing 
and may be related to a composite origin of 
increased ALP levels in obese women
14
.   
In conclusion, results of this study show that in 
severely obese women i) HLLV is a sensitive 
indicator of ectopic fat deposition, clustering with 
parameters defining the metabolic syndrome; ii) 
weight loss achieved by LAGB is associated with 
a reduction of liver volume as estimated by 
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HLLV; iii) among various anthropometric 
parameters measured, reduction of HLLV that 
follows LAGB represents the best single predictor 
of improvement of various cardiometabolic risk 
factors. 
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TABLES AND FIGURES  
 
 
 
Table. Anthropometric (A) and hematological (B) 
parameters measured in our cohort of 75 obese 
women, before and after LAGB. Hepatic Left 
Lobe Volume (HLLV), subcutaneous and intra-
abdominal fat were assessed by ultrasound. Data 
are presented as mean ± SD. Mean variations 
(calculated by subtracting data obtained after 
LAGB to those measured before LAGB) are 
 Before  After  Mean Variation (%) Statistical Sig. 
A) Anthropometric      
Body Weight (Kg) 110.7 ± 14.8 85.2 ± 11.9 −25.6 (−23.1%) p<0.001 
BMI (Kg/m
2
) 42.5 ± 4.8 32.9 ± 4.1 −9.7 (−22.7%) p<0.001 
Subcutaneous fat (mm) − SCF 40.2 ± 10.4 35.6 ± 11.6 −4.6 (−11.5%) p<0.001 
Intra-abdominal fat (mm) − IAF 79.2 ± 20.3 47.5 ± 17.7 −31.7 (−40.0%) p<0.001 
Hepatic left lobe volume (cc) − HLLV  401.9 ± 192.8 232.5 ± 86.4 −169.4 (−42.1%) p<0.001 
     
B) Laboratory measures     
Serum glucose (mg/dL) 96.8 ± 18.9 83.5 ± 8.3 −13.3 (−13.7%) p<0.001 
Uric acid (mg/dL) 5.4 ± 1.1 4.1 ± 1.2 −1.3 (−24.2%) p<0.001 
Triglycerides (mg/dL) − TG 139.1 ± 65.2 94.1 ± 35.6 −45.1 (−32.4%) p<0.001 
Total cholesterol (mg/dL) 215 ± 44.6 213.5 ± 41.5 −1.5 (−0.7%) N.S. 
HDL cholesterol (mg/dL) 54.5 ± 10 65.8 ± 14 +12.7 (+23.2%) p<0.001 
Erythrocytes sedimentation rate (mm/1h) − ESR  25.2 ± 14.3 19.4 ± 11.7 −5.6 (−22.3%) p<0.001 
Aspartate aminotransferase (U/L) − AST  22.5 ± 11.4 15.5 ± 4.9 −7 (−30.9%) p<0.001 
Alanine aminotransferase (U/L) − ALT  29.3 ± 22.7 14.6 ± 6.6 −14.8 (−50.4%) p<0.001 
-glutamyltransferase (U/L) − GGT  26.6 ± 18.8 14.1 ± 9.5 −12.5 (−46.8%) p<0.001 
Alkaline phosphatase (U/L) − ALP   188.7 ± 46.9 152.6 ± 46.1 −36.1 (−19.1%) p<0.001 
Insulin (mU/L) 16.8 ± 9 7.6 ± 4.5 −9.4 (−56.1%) p<0.001 
Leptin (ng/ml) 57.3 ± 27.6 20.6 ± 11.6 −37.1 (−64.8%) p<0.001 
HOMA index 4.1 ± 2.6 1.6 ± 1 −2.6 (−62.9%) p<0.001 
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expressed also as % variation with respect to pre-
operative values. N.S.: not significant. 
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Figure 1. Graphical plot of loadings obtained 
from the Principal Component Analysis (PCA) of 
anthropometric and hematological measurements 
of 75 obese women before LAGB. The correlation 
coefficients (absolute values) between single 
variables and the first PC (x-axis) are plotted 
against those related to the second PC (y-axis).  
The hierarchical clustering algorithm (using the 
Ward’s method), applied to the absolute values of 
loadings, identified three clusters of correlated 
 27 
variables as the optimal number of distinct 
groups. The related Voronoi diagram was also 
drawn (black lines) to highlight the separation 
borders of the three clusters. 
Hepatic left lobe volume (HLLV), HOMA index, 
insulin, intra-abdominal fat (IAF), serum glucose, 
uric acid, alkaline phosphatase (ALP), 
triglycerides (TG) and HDL cholesterol best 
clustered together (black crosses, gray area) 
whereas body weight, BMI, AST, ALT and GGT 
were grouped in a different cluster (black 
triangles). Erythrocytes sedimentation rate (ESR), 
total cholesterol, leptin and subcutaneous fat 
(SCF) clustered in a third distinct group (black 
squares). 
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Fig. 2a 
 
 
Fig. 2b 
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Fig. 2c 
 
Figure 2. Correlations between the post-surgical 
reduction of HLLV and those of serum glucose 
(upper panel), HOMA index (middle panel) or 
triglycerides (lower panel) in 75 obese women 
after LAGB. 
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Figure 3. Explained R
2
 in multivariate regression  
 31 
analyses between improvement of each hematological 
parameter (dependent variable) and anthropometric 
measures (independent variables), selected as the most 
significant by the forward stepwise algorithm. For each 
hematological parameter (plotted on the x-axis), the 
variance (i.e. R
2
 statistic expressed as percentage, y-axis) 
that is explained by various independent predictors is 
graphed using different colors.  Reductions of AST, ALT, 
serum glucose, HOMA index, GGT, insulin and 
triglycerides were mostly related to HLLV reduction 
(shown in black) whereas leptin, ESR, HDL cholesterol 
and ALP variations were mostly related to weight loss 
(shown in white). Reduction of uric acid was associated 
with reduction of intra-abdominal fat (dark gray) and with 
reduction of BMI (light gray).  
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